908 participants
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-14
- Start Date:
- 2019-04-29
- Completion:
- 2026-05-15
Conditions
- Hepatocellular Carcinoma
Interventions
- DRUG
- OTHER
No Results Yet